Novo Nordisk Faces Shareholder Unrest Amid Board Changes

Nov 14, 2025

Novo Nordisk, the Danish drugmaker known for its weight-loss and diabetes treatments, faced criticism from some minority investors during a recent reshuffle of its board of directors.

At an extraordinary shareholder meeting, investors voted on changes to the board following the decision of its main shareholder, the Novo Nordisk Foundation, to push for new appointments. Mikael Dolsten, who was previously expected to join the board, announced he would not seek election.

Despite the protests, shareholders approved Lars Rebien Sorensen as the new chairman of Novo Nordisk's board. The leadership changes come during a period of volatility for the company, with falling share prices and concerns about its recent performance in the competitive obesity drug market.

Why were some Novo Nordisk shareholders unhappy?

Some minority investors were frustrated that major changes to the board were pushed through by the company’s main shareholder without broader agreement.

Who is the new chairman of Novo Nordisk?

Lars Rebien Sorensen was approved as the new chairman at the latest shareholder meeting.

Why did Mikael Dolsten withdraw from the board election?

Mikael Dolsten announced he would not seek election to the board ahead of the meeting. No specific reasons were given in the company announcement.

How is Novo Nordisk performing in the market?

The company recently faced a drop in its share price and has had challenges keeping its lead in the obesity drug market, but some analysts remain optimistic about its future.

Sources
'Not been pretty': Novo Nordisk faces rare shareholder rebuke over board shake-u...
Reuters
Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote against a board shake-up forced through by its dominant shareholder, the Novo Nordisk Foundation.
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
GlobeNewsWire
Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November
Novo Nordisk Says Mikael Dolsten Won't Seek Election to Board at Friday's Meetin...
WSJ
The drugmaker is holding a special shareholder meeting to vote on the appointment of a new board after the pharma giant lost its lead in the obesity-drug market.
Novo Nordisk's leadership strategy tested as shareholders signal frustration ahe...
CNBC
Novo Nordisk last month announced an Extraordinary General Meeting for Nov. 14 to replace its independent board members. The weight-loss drugmaker has found itself in an increasingly chaotic situation as of late, with shares plunging and investor confidence waning.
Novo Nordisk shareholders approve new board chair
Reuters
Novo Nordisk's shareholders have approved Lars Rebien Sorensen as the company's new chairman in an extraordinary shareholder meeting, the company said on Friday.
Is It Too Late to Buy Novo Nordisk After the Drop?
The Motley Fool
Novo Nordisk (NVO 2.27%) is in the spotlight after cutting guidance again, but analysts remain optimistic. With Ozempic and Wegovy driving strong sales and a 52% upside potential, this could be one of the best comeback stories in pharma.
Retail Investors Really Don't Like Novo Nordisk (NVO) Stock
24/7 Wall Street
Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.
Novo Nordisk Stock: Buy And Forget
Seeking Alpha
Novo Nordisk A/S shares have declined more than 50% over the past 12 months. Competition in the obesity and type 2 diabetes market and pricing pressure from the U.S. government have weighed on NVO results. I think NVO stock is a long-term value play that pays a nice dividend in the meantime.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives an...
GlobeNewsWire
Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board m...
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Zacks Investment Research
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Show All Sources
Related Posts
Other News
Back to Top